The master hormone that acts as your body's repair crew—building lean muscle, burning stubborn fat, strengthening bones, and helping you recover like you did in your younger years [2][3].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Subcutaneous
Route
4 recommended
Sites
Once daily
Frequency
Preparation
Bacteriostatic water (BAC water)—the benzyl alcohol preservative keeps it sterile for multiple uses
Insulin syringes (29-31 gauge)—smaller gauge means less discomfort
Alcohol swabs for cleaning vial tops and injection sites
Your HGH powder vial
Optional: multi-use vial adapter for easier drawing
Pro tip
Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.
Mixing
Wash your hands thoroughly with soap and water. Gather all supplies on a clean, flat surface.
Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol swab. Let it air dry.
Draw the appropriate amount of bacteriostatic water into a sterile syringe.
Insert the needle into the vial at an angle, aiming at the inside wall of the vial. Slowly push the plunger to let the water trickle down the glass wall -- do NOT squirt directly onto the powder.
Once all water is added, gently swirl the vial in a slow circular motion. Never shake the vial, as this can damage the peptide bonds.
Continue swirling until the powder is completely dissolved and the solution is clear. If particles remain, let the vial sit for a few minutes and swirl again.
Label the vial with the date of reconstitution, the peptide name, and the concentration (e.g. 250mcg per 0.1mL).
Example calculation
If you have a 10 IU vial and add 1mL of BAC water, you get 10 IU/mL. Each 0.1mL (10 units on an insulin syringe) equals 1 IU of HGH. For a 2 IU dose, you'd draw 0.2mL (20 units).
Dose calculation
For a 2 IU dose at 10 IU/mL concentration: draw 0.2mL (20 units on a standard insulin syringe with 100 unit markings). Always double-check your math—HGH is expensive and you don't want to waste it or underdose.
Pro tip
Always add the bacteriostatic water slowly, letting it run down the side of the vial. Never shake the vial -- swirl gently to avoid damaging the peptide.
Location
Site 01
Abdomen
Pinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
Site 02
Outer Thigh
Middle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
Site 03
Upper Arm
Back or outer area of the upper arm. This site may require assistance from another person for proper technique.
Site 04
Gluteal
Upper outer quadrant of the buttock. This site is best for intramuscular injections and larger volumes.
Rotate between 4 sites to prevent tissue buildup and ensure consistent absorption.
Pro tip
Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.
Step by step
Wash your hands thoroughly with soap and water
Let the HGH vial reach room temperature if refrigerated (5-10 minutes)
Clean the vial top and injection site with alcohol swabs
Draw your dose slowly and carefully—avoid shaking or agitating the solution
Pinch about an inch of skin and insert needle at 45-90 degree angle
Inject slowly over 5-10 seconds
Wait a few seconds before withdrawing the needle
Apply gentle pressure—don't rub the area
Pro tip
This peptide uses subcutaneous injection (into the fat layer just under the skin)—the most common and easiest method for self-administration. Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.
Timing
Optimal timing
Best time
Most people inject first thing in the morning on an empty stomach, or before bed. Morning dosing mimics your body's natural GH pulse and avoids potential sleep disruption. Evening/bedtime dosing can enhance the natural nighttime GH surge during deep sleep [8][9].
With food?
Best taken on an empty stomach. Insulin and blood sugar spikes from food can blunt HGH's effects. Wait at least 30-60 minutes after injection before eating, especially carbohydrates. Some users inject 2-3 hours after their last meal.
Stacking notes
If combining with peptides like CJC-1295 or Ipamorelin, you can inject at the same time but use different sites. Space HGH away from meals by at least 30 minutes. If using insulin (only under medical supervision), timing becomes critical—consult a physician [16].
Sample daily schedule
Morning (immediately upon waking, 6-7 AM)
Full daily dose (e.g., 2 IU) injection
Site: Rotate between belly, thigh, and arm
This is the most popular timing. Inject on an empty stomach and wait 30-60 minutes before eating breakfast. This mimics your body's natural morning GH pulse and gives you energy for the day.
Split dosing: Morning + Bedtime
Half in AM (e.g., 1 IU), half before bed (e.g., 1 IU) injection
Site: Different sites for each injection
Some users prefer splitting their dose to maintain steadier blood levels. The nighttime dose can enhance the natural GH surge during deep sleep. This protocol may help reduce side effects from a single larger dose.
Dosing tiers
Dose
0.15-0.30 mg/day (approx. 0.2 mg/day)
Frequency
Once daily
Duration
First 1-2 months before titration
FDA-labeled non-weight-based starting dose for adult growth hormone deficiency (Genotropin) [6]. Lower starting doses and smaller increments are advised for older patients [6].
Dose
Titrate by 0.1-0.2 mg/day to target (commonly 0.2-0.6 mg/day)
Frequency
Once daily
Duration
Adjusted every 1-2 months
Dose titrated every 1-2 months to clinical response and serum IGF-1 per FDA label [6].
Dose
Not more than 0.04 mg/kg/week initially, up to 0.08 mg/kg/week
Frequency
Divided into 6-7 daily injections
Duration
Titrated at 4-8 week intervals
FDA-labeled weight-based regimen ceiling for adult GH deficiency (Genotropin) [6].
Preservation
Before mixing
Keep unopened HGH vials refrigerated at 36-46°F (2-8°C). Protect from light and keep in original packaging. Never freeze powder form. Most pharmaceutical HGH has an 18-24 month shelf life when properly stored. Check expiration dates.
After mixing
Refrigerate immediately after mixing at 36-46°F (2-8°C). Never freeze reconstituted HGH—freezing denatures the protein and destroys the hormone. Avoid shaking—swirl gently if needed. Use within 28 days. Keep away from light.
Shelf life after mixing
28 days
Signs of degradation
Discard the vial immediately if you notice any of these:
Cloudy or hazy solution (should be crystal clear)
Visible particles, floaters, or sediment
Any color change—should be colorless
Unusual smell or odor
Important
When to stop
Severe or persistent headaches with vision changes—may indicate intracranial pressure
Significant swelling that doesn't improve with dose reduction
Blood sugar levels becoming diabetic range despite management
Development of new growths, lumps, or concerning symptoms
Severe joint pain or carpal tunnel that interferes with daily life
Any allergic reaction—hives, difficulty breathing, facial swelling
Human Growth Hormone is a prescription medication in most countries. This information is for educational purposes only and does not constitute medical advice. Always work with a qualified healthcare provider before starting, stopping, or adjusting HGH therapy. Regular monitoring through blood tests is essential for safe use.
Clean technique checklist
Wash hands thoroughly with soap and water before handling supplies
Swab vial tops and injection site with alcohol and let dry
Never touch the needle tip or allow it to contact non-sterile surfaces
Use a new syringe and needle for each injection
Dispose of used sharps in a proper sharps container
Store reconstituted peptides according to the storage instructions above
Published research
Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, et al. · 2025
This comprehensive review found that growth hormone plays a key role in body composition, muscle mass, bone formation, and metabolism. While showing promising anti-aging effects, the review emphasizes that long-term safety and efficacy for healthy aging still require more research.
Sun F, Yang A, Jin Y, et al. · 2025
This meta-analysis of 10 randomized trials found that low-dose HGH therapy significantly reduces visceral (belly) fat and increases thigh muscle mass in obese individuals. No serious adverse events were reported, suggesting low-dose HGH may help with sarcopenic obesity.
Xu Q, Yang Y, Ke J, et al. · 2025
This study showed that continued HGH therapy significantly improved bone mineral density and grip strength in patients with GH deficiency. Patients who stopped treatment experienced bone density decline and worsening lipid profiles, highlighting the importance of appropriate treatment duration.
Woelfle J, Kreitschmann-Andermahr I, Strasburger CJ, et al. · 2025
This real-world registry study documented the first 100 patients on newer long-acting GH formulations, providing insights into dosing patterns and patient selection outside clinical trials. The study highlights evolving treatment approaches in GH therapy.
Cianfarani S · 2025
This review explored how individual responses to GH therapy vary significantly despite standardized protocols, emphasizing the need for personalized approaches. The study highlights that treatment success depends on diagnosis, patient factors, and proper dose optimization.
Pfizer (FDA label) · 2020
FDA-labeled adult growth hormone deficiency dosing: non-weight-based start ~0.2 mg/day (0.15-0.30 mg/day) titrated every 1-2 months by 0.1-0.2 mg/day; weight-based start not more than 0.04 mg/kg/week up to 0.08 mg/kg/week, given as daily subcutaneous injections.
Rudman D, Feller AG, Nagraj HS, et al. · 1990
Six-month controlled trial in 21 healthy men aged 61-81 with low IGF-1 levels. Growth hormone treatment increased lean body mass by 8.8%, decreased adipose tissue mass by 14.4%, and increased skin thickness by 7.1%, suggesting diminished GH secretion contributes to the loss of lean mass and skin thinning seen in old age.
Iranmanesh A, Lizarralde G, Veldhuis JD · 1991
24-hour blood sampling study in 21 healthy men aged 21-71. Each decade of increasing age reduced the daily GH production rate by about 14%, with age and body mass index together accounting for more than 60% of the variability in 24-hour GH production.
Van Cauter E, Plat L · 1996
Review of GH secretion during sleep. In adults, the most reproducible GH pulse occurs shortly after sleep onset in association with the first phase of slow-wave (deep) sleep; in men roughly 70% of sleep GH pulses coincide with slow-wave sleep, and sleep-related secretion depends primarily on growth hormone-releasing hormone.
Doessing S, Heinemeier KM, Holm L, et al. · 2010
Fourteen days of growth hormone administration in healthy young adults increased collagen synthesis in tendon and skeletal muscle (tendon collagen I mRNA rose 3.9-fold) without affecting myofibrillar protein synthesis, indicating GH primarily strengthens connective/matrix tissue rather than directly driving muscle-cell growth.
Herndon DN, Barrow RE, Kunkel KR, et al. · 1990
Randomized double-blind trial in 40 severely burned children. Recombinant growth hormone at 0.2 mg/kg/day significantly shortened skin-graft donor-site healing time and reduced hospital stay from 0.80 to 0.54 days per percent of body surface burned.
Liu H, Bravata DM, Olkin I, et al. · 2007
Systematic review of randomized trials of GH in healthy elderly people (31 articles, 18 study populations). GH produced small body-composition changes (about 2.1 kg less fat and 2.1 kg more lean mass) but treated participants were significantly more likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia. The review also notes that distribution of GH as an anti-aging agent is illegal in the United States.
Moller N, Jorgensen JO · 2009
Comprehensive review of GH metabolic actions in humans. The most prominent metabolic effect of GH is a marked increase in lipolysis and free fatty acid levels; GH also increases protein synthesis and antagonizes insulin's effects on glucose metabolism, which explains its ability to induce insulin resistance.
Ayyar VS · 2011
Historical review of growth hormone therapy. After cadaver-derived GH was discontinued in April 1985 because of Creutzfeldt-Jakob disease cases, the FDA rapidly approved Genentech's recombinant (synthetic) growth hormone, which was introduced in the United States in 1985.
Baumann GP · 2012
Review of GH doping in sports. GH use in athletic competition is banned by the World Anti-Doping Agency; the blood-based isoform test distinguishes recombinant GH from endogenous GH within roughly 12-24 hours of the last dose, and a biomarker test extends the detection window to 1-2 weeks.
Sigalos JT, Pastuszak AW · 2018
Review of growth hormone secretagogues, including GH-releasing peptides. These agents promote pulsatile release of the body's own GH, which remains subject to negative feedback and can prevent supra-therapeutic GH levels; available studies indicate they are well tolerated, with some concern for increased blood glucose from decreased insulin sensitivity.
Boguszewski CL, Boguszewski MCDS · 2019
Endocrine Reviews analysis of the relationship between the GH axis and cancer. Replacement GH therapy in GH-deficient adults and short children has been shown to be safe when no other risk factors for malignancy are present, while caution is advised in cancer survivors and certain genetic syndromes.
Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, et al. · 2009
Prospective 10-year study of continuous GH replacement in 109 GH-deficient adults. Treatment produced a sustained increase in lean mass and, after correction for age and gender, sustained and partly progressive increases in muscle strength, with approximately normalized muscle strength after 10 years of uninterrupted use.
Head to head